PANTOPRAZOLE SODIUM - Generic Drug Details

What are the generic drug sources for pantoprazole sodium and what is the scope of patent protection?

Pantoprazole sodium is the generic ingredient in four branded drugs marketed by Ajanta Pharma Ltd, Annora Pharma, Aurobindo Pharma Ltd, Cipla, Dexcel, Sun Pharm, Wyeth Pharms, Alembic, Aspiro, Be Pharms, Deva Holding As, Epic Pharma Llc, Eugia Pharma, Gland, Hangzhou Zhongmei, Knack, Meitheal, Pharmobedient, Sandoz, Fresenius Kabi Usa, Hikma, Baxter Hlthcare Corp, Actavis Totowa, Amneal Pharms, Apotex, Dr Reddys Labs Ltd, Granules, Graviti Pharms, Hetero Labs Ltd V, Ingenus Pharms Llc, Jubilant Generics, L Perrigo Co, Lannett Co Inc, Macleods Pharms Ltd, Mankind Pharma, Mylan Pharms Inc, Orbion Pharms, Rubicon Research, Sun Pharm Inds Ltd, Teva, and Torrent Pharms, and is included in forty-six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Pantoprazole sodium has thirty-five patent family members in twenty-eight countries.

There are forty-eight drug master file entries for pantoprazole sodium. Sixty-six suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for PANTOPRAZOLE SODIUM

International Patents:	35
US Patents:	1
Tradenames:	4
Applicants:	41
NDAs:	46
Drug Master File Entries:	48
Finished Product Suppliers / Packagers:	66
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	23
Patent Applications:	7,136
Drug Prices:	Drug price trends for PANTOPRAZOLE SODIUM
Drug Sales Revenues:	Drug sales revenues for PANTOPRAZOLE SODIUM
What excipients (inactive ingredients) are in PANTOPRAZOLE SODIUM?	PANTOPRAZOLE SODIUM excipients list
DailyMed Link:	PANTOPRAZOLE SODIUM at DailyMed

See drug prices for PANTOPRAZOLE SODIUM

See drug sales revenues for PANTOPRAZOLE SODIUM

Recent Clinical Trials for PANTOPRAZOLE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alexandria University	Phase 3
Mansoura University	Phase 1/Phase 2
Federal University of São Paulo	Phase 4

See all PANTOPRAZOLE SODIUM clinical trials

Generic filers with tentative approvals for PANTOPRAZOLE SODIUM

Applicant	Application No.	Strength	Dosage Form
		40MG	INJECTABLE; INJECTION
		EQ 40MG BASE/VIAL	POWDER;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for PANTOPRAZOLE SODIUM

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for PANTOPRAZOLE SODIUM

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for PANTOPRAZOLE SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROTONIX	for Delayed-release Oral Suspension	pantoprazole sodium	40 mg	022020	1	2019-09-13
PROTONIX IV	For Injection	pantoprazole sodium	40 mg/vial	020988	1	2005-04-07
PROTONIX	Delayed-release Tablets	pantoprazole sodium	20 mg and 40 mg	020987		2004-02-02

US Patents and Regulatory Information for PANTOPRAZOLE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jubilant Generics	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	090901-002	Aug 30, 2011		DISCN	No	No
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	AP	RX	Yes	Yes
Rubicon Research	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	090807-002	May 2, 2012	AB	RX	No	No
Lannett Co Inc	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	078281-002	Jan 20, 2011	AB	RX	No	No
Meitheal	PANTOPRAZOLE SODIUM	pantoprazole sodium	INJECTABLE;INTRAVENOUS	215860-001	Aug 29, 2022	AP	RX	No	No
Graviti Pharms	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	219087-002	Jan 16, 2025	AB	RX	No	No
Aurobindo Pharma Ltd	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	202038-001	Sep 28, 2012	AB	RX	No	No

Expired US Patents for PANTOPRAZOLE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-001	Feb 2, 2000	5,997,903*PED
Wyeth Pharms	PROTONIX	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022020-001	Nov 14, 2007	4,758,579*PED
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-002	Jun 12, 2001	5,997,903*PED
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	6,780,881*PED
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-002	Jun 12, 2001	4,758,579*PED
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-001	Feb 2, 2000	4,758,579*PED
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	8,754,108*PED

International Patents for PANTOPRAZOLE SODIUM

Country	Patent Number	Title	Estimated Expiration
South Korea	101141508
Hong Kong	1086766	潘托拉唑多粒型調配物 (PANTOPRAZOLE MULTIPARTICULATE FORMULATIONS)
Russian Federation	2006114690	СОСТАВЫ ПАНТОПРАЗОЛА, СОСТОЯЩИЕ ИЗ МНОЖЕСТВА ЧАСТИЦ
China	1886119	Pantoprazole multiparticulate formulations
Taiwan	200524643	Pantoprazole multiparticulate formulations
Russian Federation	2361574	СОСТАВЫ ПАНТОПРАЗОЛА, СОСТОЯЩИЕ ИЗ МНОЖЕСТВА ЧАСТИЦ (PANTOPRAZOLE COMPOUNDS CONSISTING OF SET OF PARTICLES)
Argentina	045956	MULTIPARTICULAS DE PANTOPRAZOL Y FORMULACION QUE LAS CONTIENE

Supplementary Protection Certificates for PANTOPRAZOLE SODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0166287	SPC/GB96/056	United Kingdom		PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
0166287	96C0032	Belgium		PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506

Market Dynamics and Financial Trajectory for Pantoprazole Sodium

Last updated: February 19, 2026

What is the current market size and growth rate for pantoprazole sodium?

The global proton pump inhibitor (PPI) market, which includes pantoprazole sodium, was valued at approximately USD 13.8 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2022 to 2028. Pantoprazole sodium accounts for roughly 8-10% of this market, driven by its use in GERD, Zollinger-Ellison syndrome, and erosive esophagitis.

How competitive is the pantoprazole sodium market?

Major players include:

• Pfizer Inc. ("Protonix")
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sandoz (Novartis)
• Aurobindo Pharma

Pfizer's Protonix remains the leading formulation. Patent expirations for brand-name versions in the U.S. occurred in 2014, opening the market to generics. Generics dominate sales, representing approximately 60% of total pantoprazole sodium revenue globally.

What are the patents and regulatory barriers affecting market entry?

Pfizer's original patents on pantoprazole sodium expired in 2014 in the U.S., but certain formulations gained extended exclusivity through secondary patents and formulation-specific claims until 2020. The expiry of patents in key markets like the U.S. and Europe facilitated generics' entry.

Regulatory approval processes are generally straightforward due to established biosimilar pathways. However, patent litigations may delay generic market entry in some jurisdictions.

What trends influence the financial trajectory?

• Increasing prevalence of GERD and related disorders: Global GERD prevalence is approximately 20%, driving sustained demand.
• Patent expirations: Expected manufactured generic proliferation post-2014, matching sales declines of proprietary brands.
• Price erosion: Entry of generics has reduced average selling prices (ASPs) by 30-50%, affecting revenue.
• Rise of OTC formulations: Moving from prescription-only to OTC status in some regions expands market size, but pressures prices.
• Manufacturing changes: Companies adopting cost-effective APIs and formulations reduce production costs and improve margins.

How do supply chain and manufacturing factors impact the outlook?

Supply chain disruptions, such as raw material shortages (e.g., omeprazole intermediates), can impact production volumes. Companies investing in vertical integration mitigate some risks. API cost reductions from process innovations support competitiveness.

Financial projections: Revenue and profit prospects

Year	Estimated Global Sales (USD billions)	Key Drivers	Comments
2022	2.5 – 2.7	Generics market share expansion	Market stabilization after patent expiry
2024	2.3 – 2.5	Price erosion, competitive intensification	Margin impact from pricing pressures
2026	2.0 – 2.2	Market saturation, OTC shift	Revenue plateau unless new indications emerge

Profitability depends heavily on manufacturing efficiencies and patent litigation outcomes. Companies that innovate or diversify formulation offerings may see improved margins.

Summary of key market drivers and risks

• Market drivers: Rising GERD prevalence, patent expirations, OTC availability.
• Risks: Price erosion, regulatory delays, raw material shortages, increased competition.

Key Takeaways

• The pantoprazole sodium market is mature, with significant generic penetration reducing prices.
• Estimated global sales hover around USD 2.5 billion, with slow growth projected post-2024.
• Patent expirations and OTC conversions will influence supply dynamics.
• Supply chain stability and production innovation are critical for maintaining margins.
• Emerging markets and new indications may present growth opportunities despite market saturation.

FAQs

Q1: How does patent expiry affect pantoprazole sodium's market?

A1: Patent expiry opens markets to generics, increases competition, and drives down prices, leading to revenue declines for branded formulations.

Q2: What are the main drivers for future growth?

A2: Rising prevalence of acid-related disorders and expansion into OTC segments are primary growth drivers.

Q3: How are generic manufacturers impacting the market?

A3: They provide lower-cost alternatives, capturing a majority share of sales, and exert downward pressure on ASPs.

Q4: Are there new indications or formulations expected to influence market size?

A4: Few new indications are projected; however, formulations with improved delivery or combination therapies might offer niche growth.

Q5: What are the primary risks facing companies in this market?

A5: Price erosion due to generics, supply chain disruptions, and regulatory hurdles are significant risks.

---

References

1. Grand View Research. (2022). Proton Pump Inhibitors Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com
2. U.S. Food and Drug Administration. (2022). Patent Status of Proton Pump Inhibitors. Retrieved from https://www.fda.gov
3. Statista. (2022). GERD prevalence worldwide. Retrieved from https://www.statista.com